Your browser doesn't support javascript.
loading
Activity of Gut-Derived Nisin-like Lantibiotics against Human Gut Pathogens and Commensals.
Zhang, Zhenrun J; Wu, Chunyu; Moreira, Ryan; Dorantes, Darian; Pappas, Téa; Sundararajan, Anitha; Lin, Huaiying; Pamer, Eric G; van der Donk, Wilfred A.
Afiliação
  • Zhang ZJ; Duchossois Family Institute, University of Chicago, Chicago, Illinois 60637, United States.
  • Wu C; Department of Microbiology, University of Chicago, Chicago, Illinois 60637, United States.
  • Moreira R; Department of Biochemistry, University of Illinois at Urbana─Champaign, Urbana, Illinois 61801, United States.
  • Dorantes D; Department of Chemistry, The Howard Hughes Medical Institute, University of Illinois at Urbana─Champaign, Urbana, Illinois 61801, United States.
  • Pappas T; Department of Biochemistry, University of Illinois at Urbana─Champaign, Urbana, Illinois 61801, United States.
  • Sundararajan A; Duchossois Family Institute, University of Chicago, Chicago, Illinois 60637, United States.
  • Lin H; Duchossois Family Institute, University of Chicago, Chicago, Illinois 60637, United States.
  • Pamer EG; Duchossois Family Institute, University of Chicago, Chicago, Illinois 60637, United States.
  • van der Donk WA; Duchossois Family Institute, University of Chicago, Chicago, Illinois 60637, United States.
ACS Chem Biol ; 19(2): 357-369, 2024 02 16.
Article em En | MEDLINE | ID: mdl-38293740
ABSTRACT
Recent advances in sequencing techniques unveiled the vast potential of ribosomally synthesized and post-translationally modified peptides (RiPPs) encoded in microbiomes. Class I lantibiotics such as nisin A, widely used as a food preservative, have been investigated for their efficacy in killing pathogens. However, the impact of nisin and nisin-like class I lantibiotics on commensal bacteria residing in the human gut remains unclear. Here, we report six gut-derived class I lantibiotics that are close homologues of nisin, four of which are novel. We applied an improved lantibiotic expression platform to produce and purify these lantibiotics for antimicrobial assays. We determined their minimal inhibitory concentration (MIC) against both Gram-positive human pathogens and gut commensals and profiled the lantibiotic resistance genes in these pathogens and commensals. Structure-activity relationship (SAR) studies with analogs revealed key regions and residues that impact their antimicrobial properties. Our characterization and SAR studies of nisin-like lantibiotics against both pathogens and human gut commensals could shed light on the future development of lantibiotic-based therapeutics and food preservatives.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bacteriocinas / Nisina Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bacteriocinas / Nisina Idioma: En Ano de publicação: 2024 Tipo de documento: Article